77 results
Page 2 of 4
6-K
EX-99.1
euwqmv45
5 Oct 21
ERYTECH Announces Maximum Tolerated Dose Declared in a Phase 1 Investigator Sponsored Trial of Eryaspase in First-Line Pancreatic Cancer
12:34pm
F-3
cmlfg
21 Sep 21
Shelf registration (foreign)
12:50pm
6-K
EX-99.1
9rkk 5q9t
21 Sep 21
ERYTECH Provides Business Update and Reports Financial Results for the First Half of 2021
9:42am
6-K
EX-99.1
vz6a7 5xbfx
20 Sep 21
I.Certification of the Person Responsible for the Half-year Financial Report
1:37pm
6-K
EX-99.1
f13u03yp7lpypdtayst
30 Jul 21
ERYTECH Granted U.S. FDA Fast Track Designation for Eryaspase in Hypersensitive ALL
10:09am
6-K
EX-99.1
v5gyxfo
26 Jul 21
Current report (foreign)
11:47am
6-K
EX-99.1
kz0a u9mzt8kb
29 Jun 21
Current report (foreign)
8:18am
6-K
EX-99.1
wc2g eaf9o
26 May 21
Live webcast of the Shareholders’ Meeting
9:55am
6-K
EX-99.1
sqpy 3d54i
7 May 21
ERYTECH Provides Business Update and Reports Financial Results for the First Quarter of 2021
6:13am
424B5
jw4c ddr9p9cah2
5 May 21
Prospectus supplement for primary offering
4:50pm
6-K
EX-99.1
1aio3j5riam8xo
3 May 21
ERYTECH Announces $30.0 Million
5:20pm
424B5
p4a7xaextn1y9ngzqg2
3 May 21
Prospectus supplement for primary offering
5:14pm
6-K
EX-99.1
nwdq7e1ty2lm1 7t4w
3 May 21
ERYTECH Reports Cash Balance at End of Q1 2021
6:07am
6-K
EX-99.2
dxs0rm0v
3 May 21
ERYTECH Reports Cash Balance at End of Q1 2021
6:07am
6-K
EX-99.1
ommmoa6mv08 adpqj
21 Apr 21
ERYTECH Requested a Pre-BLA Meeting with the FDA
8:01am
6-K
EX-99.1
dycib jn76wkn548x
19 Apr 21
ERYTECH Announces Completion of First Cohort in a Phase 1 Investigator Sponsored Trial of
9:48am
6-K
EX-99.1
46ktjjo7l b34j94fp
9 Mar 21
ERYTECH Provides Business Update and Reports Financial Results for the Full Year 2020
9:55am
6-K
EX-99.1
vx2vc5tq7q6elolqq99n
8 Feb 21
ERYTECH Announces TRYbeCA-1 Phase 3 Trial
9:15am
6-K
EX-99.1
glhqcflzjut70i
27 Jan 21
ERYTECH Highlights 2021 Milestones
10:17am